Close

Trialbee and uMotif Simplify and Expand Patient Access to Global Clinical Trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...
- Advertisement -

The increasing need for speed and efficiency in clinical research has created more urgency to streamline and simplify the patient journey. Trialbee, a patient matching and enrolment platform, and uMotif, a patient-centric data capture provider, are partnering to improve the patient experience and improve trial accessibility globally.

The new partnership streamlines the end-to-end patient journey through a lightweight, data-driven solution that removes the need for multiple apps or systems. The companies’ integrated platforms simplify trial activities from initial awareness through enrollment and data collection during study conduct and close-out, optimising the patient experience to achieve greater compliance for protocol requirements and increased retention.

“Technology is changing the way clinical trials are run, presenting new opportunities to expand patient access, especially among historically underrepresented patient groups, and bring life saving drugs and devices to market efficiently and effectively,” says Matt Walz, CEO of Trialbee. “Through this partnership, Trialbee and uMotif are transforming clinical trials to benefit global patients, trials sponsors, CROs, investigative sites and other stakeholders.”

Patients are digitally matched to study protocols via Trialbee HIVE™, the real-world data (RWD) driven patient matching platform that accelerates recruitment using global data assets, look-alike modelling, and a scalable nurse qualification process.  Qualified, study-ready patients are then consented at-site or remotely through the Trialbee platform, which is integrated with uMotif’s application.

Once enrolled, patients use the engaging uMotif app to capture large volumes of high quality ePRO, eDiary and symptom data in real-time throughout the duration of a trial. Patients are empowered to manage and collect their data in an easy-to-use application, while sponsors receive a better understanding of patient symptoms and behavior.

“uMotif’s collaboration with Trialbee supports our mission to provide a more seamless experience for patients and clinical trial professionals including sponsors, CROs and sites. Our human-centred and design-led approach means our technology powers the capture of large volumes of high-quality patient data, via BYOD and/or provisioned devices. Empowering patients to capture their data remotely through a Decentralized Clinical Trial approach removes site burden and potential bias, supporting more efficient trials.” Said Bruce Hellman, CEO of uMotif.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »